Cardionovum

Be up
to date.

Latest press release

Cardionovum® Takes the Spotlight in Vascular News journal: Prof. Tozzi's Insights about Aperto 600 Study

Cardionovum® is present in the Vascular News’s November edition with an article in which Prof. Tozzi (Varese, Italy) shares the clinical outcomes of the Aperto 600 Study, in which more than 600 Aperto® DCBs have been used in ArteriousVenous Fistula (AVF) and ArteriousVenous Graft (AVG), including a large number of Central Vein Stenosis (CVS).

Learn more >>

XLIMUS® DES: XLIMIT Trial results published on Frontiers in Cardiovascular Medicine journal

Cardionovum® announces that the XLIMIT Trial results, featuring the XLIMUS® DES, have been published online in the Frontiers in Cardiovascular Medicine journal with the article entitled “A randomized control trial to assess optical coherence tomography parameters of the Xlimus drug-eluting stent: the XLIMIT trial”.

 

XLIMIT is a non-inferiority, prospective, multicenter, randomized, controlled trial in which a total of 177 patients were enrolled and randomized in two groups in a 2:1 ratio (2 XLIMUS®:1 Synergy™).

The primary endpoint of this study has been defined as the in-stent neointimal volume weighted by the sum of the lengths of implanted stent (ISNV), and the in-stent percent neointimal volume obstruction (%VO) were evaluated at 6-9 months by means of Optical Coherence Tomography (OCT).

Learn more >>

RESTORE® HYPER study results published on Minerva Cardiology and Angiology journal

Cardionovum® announces that the HYPER Study results, featuring the innovative RESTORE®  DEB, have been published online in the Minerva Cardiology and Angiology journal, with the article entitled "Procedural and one-year outcomes following drug-eluting stent and drug-coated balloon combination for the treatment of de novo diffuse coronary artery disease: the HYPER Study”.

 

The HYPER is a prospective, multicenter study including patients affected by de novo diffuse CAD treated with a hybrid approach from April 2019 to December 2020, having as primary endpoint the evaluation of the 1-year device-oriented composite endpoint (DoCE, cardiac death, target vessel myocardial infarction and ischemia-driven target lesion revascularization [ID-TLR]).

Learn more >>

Dott. Ielasi discusses about the results of the 2 years clinical outcomes of the HYPER Study and the benefits of RESTORE® DEB

Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2023 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.

 

In this video interview, Dott. Ielasi summarizes the benefits of RESTORE® paclitaxel eluting balloon and comments the results of the Hyper study at 2 years, putting a focus on the encouraging results of the combined use of modern DES and RESTORE® DEB in the context of de novo diffuse CAD: in detail, results showed a 2-year clinical follow-up available for the vast majority of the patients enrolled (n=105/106, 99%) and a low incidence of Device oriented Composite Endpoint (DoCE) equal to 4.6% at 24 months.

 

In conclusion, even if larger and more robust data from RCTs (vs. full metal jacket PCIs) are needed to confirm the findings, the HYPER study reports very encouraging results in terms of safety and efficacy of the hybrid approach in the treatment of diffuse CAD.

Learn more >>

Prof. Tozzi discusses about Aperto® drug-coated balloon as a “first-line” treatment of neointimal hyperplasia in ArterioVenous Fistula (AVF) lesions and CVS

Prof. Matteo Tozzi (Varese, Italy) spoke to Vascular News at Charing Cross 2023 meeting held in London (England) about the variety of vascular access complications and their treatment options.

 

In this video-interview, Prof. Tozzi commented as fantastic the clinical outcomes of Aperto® DCB in his recent analysis, in which more than 600 Aperto® DCB have been used in ArteriousVenous Fistula (AVF) and AVG, including a large number of Central Vein Stenosis (CVS).

Learn more >>

Dr. Lichtenberg discusses about Aperto® drug-coated balloon technology and its promising results in dialysis access patients

Prof. Michael Lichtenberg (Arnsberg, Germany) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about the importance on new endovascular strategies, such as Drug-Coated Balloons (DCBs), to improve patency rates in patients with consecutive neointimal hyperplasia in haemodialysis access.

 

In this interview, a particular focus is put on the promising results of APERTO® OTW, our high-pressure paclitaxel releasing DCB, considered as “one of the very promising new technologies” for treating restenosis in dialysis access patients

Learn more >>

Upcoming events

Cardionovum® at GISE 2024

Cardionovum® is pleased to invite you to visit us at booth #43.

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano
Italy

Date: Nov 19, 2024–Nov 23, 2024

Latest events

Cardionovum® at EuroPCR 2024

Cardionovum® is pleased to invite you to visit us at booth #M14.

Location:

Palais des Congrès de Paris
2 Place Porte Maillot
Paris - FRANCE

Date: May 14, 2024–May 18, 2024

Cardionovum® at 12 Westdeutsches Gefäßsymposium

Cardionovum® is pleased to invite you to visit us at our booth during the Westdeutsches Gefäßsymposium.

Location:

Congress Centrum Oberhausen
Düppelstraße 1
46045 Oberhausen, Germany

Date: Feb 16, 2024–Feb 18, 2024

Cardionovum® at DEBS

Cardionovum® is pleased to invite you to visit us during Drug Eluting Balloon Spark (DEBS) 2024.

Location:

NH Collection Vittorio Veneto
Corso d’Italia 1,
00198, Rome, Italy

Cardionovum® also invite you to attend the presentation by our CTO Massimo Morero entitled “Amorphous DCB carrier for uniform coating and higher deliverability in complex situations” on 19th January from 17:30 to 17:40 in the Congress Hall.

Date: Jan 18, 2024–Jan 21, 2024

go top